Compare Moderna, Inc. (MRNA) vs Vaxcyte Inc. Common Stock (PCVX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Vaxcyte Inc. Common Stock — how do they compare? Moderna, Inc. trades at $220.8 (market cap $86.33B), while Vaxcyte Inc. Common Stock trades at $67.27 (market cap $10.51B). The key difference: Moderna, Inc. is far larger — about 8.2× Vaxcyte Inc. Common Stock's market cap, and Moderna, Inc. is trading nearer its 52-week high, Vaxcyte Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Vaxcyte Inc. Common Stock for 0 Days on average.
| MRNA | PCVX | |
|---|---|---|
Market Cap | $86.33B | $10.51B |
Volume | 13,361,426 | 2,644,694 |
Sector | Health | Health |
52-Week High | $226.30 | $73.82 |
52-Week Low | $22.36 | $40.32 |
Typical Hold Time | 59 Days | 0 Days |
Enterprise Value | $82.48B | $9.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $226.30, up 5.88% with strong technical momentum as it joins the Nasdaq-100 index. Despite beating Q2 2026 EPS estimates, the company faces fundamental challenges with negative profitability margins (-142.58% net income margin) and declining revenue from pandemic peaks. Technical indicators show bullish momentum with price above key support levels, while analyst sentiment remains divided with a $115.70 consensus target well below current levels.
The outlook balances Nasdaq inclusion benefits against valuation concerns after a 500% 2026 rally. Investment opportunity lies in the cancer vaccine pipeline growth, while risks include sustained profitability challenges and high valuation multiples (P/S 38.5) that may not justify current price levels given declining revenue trends.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Vaxcyte Inc. Common Stock
Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →
